RBF Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

RBF Capital’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,971	Closed	-$54.9K	–	606
2024 Q1	$54.9K	Sell	10,971 -320	-3%	-$1.99K	﹤0.01%	543
2023 Q4	$76K	Sell	11,291 -1,751	-13%	-$15.4K	﹤0.01%	533
2023 Q3	$119K	Hold	13,042	–	–	0.01%	503
2023 Q2	$275K	Buy	+13,042	New	+$402K	0.02%	439

Other funds holding EIGR

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

RBF Capital's EIGR Position: Q2 2024 in Review

RBF Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 10,971 shares — an estimated $54.9K sold.

RBF Capital first reported a position in EIGR in Q2 2023 and held it in 4 quarters. The position peaked at $275K in Q2 2023. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.

RBF Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
RBF Capital sold 10,971 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $54.9K.
RBF Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2023 and held it in 4 quarters.
RBF Capital's Eiger BioPharmaceuticals, Inc. position peaked at $275K in Q2 2023.
2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.

Based on RBF Capital's 13F filing for Q2 2024, filed 14 Aug 2024.